Mast Cells as Drivers of Disease and Therapeutic Targets

被引：98
|
作者：
Siebenhaar, Frank [1 ]
Redegeld, Frank A. [2 ]
Bischoff, Stephan C. [3 ]
Gibbs, Bernhard F. [4 ,5 ]
Maurer, Marcus [1 ]
机构：
[1] Charite, Dept Dermatol & Allergy, Berlin, Germany
[2] Univ Utrecht, Div Pharmacol, Dept Pharmaceut Sci, Fac Sci, Utrecht, Netherlands
[3] Univ Hohenheim, Dept Nutr Med & Immunol, Stuttgart, Germany
[4] Univ Kent, Medway Sch Pharm, Canterbury, Kent, England
[5] Carl von Ossietzky Univ Oldenburg, Dept Dermatol & Allergol, Oldenburg, Germany
来源：
TRENDS IN IMMUNOLOGY | 2018年 / 39卷 / 02期
关键词：
RECEPTOR ANTAGONISTS; SYSTEMIC MASTOCYTOSIS; SKIN INFLAMMATION; CATHEPSIN-G; ALLERGEN; DEGRANULATION; INHIBITION; OMALIZUMAB; MEDIATORS; EFFICACY;
D O I：
10.1016/j.it.2017.10.005
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Mast cells (MCs) contribute to the pathogenesis of a multitude of diseases that include MC-driven disorders such as urticaria, type I allergies, and mastocytosis as well as autoimmune and other inflammatory disorders and malignant tumors. Here, we review and discuss the results of studies that identified and characterized how MCs contribute to disease and, importantly, what strategies may be used to target MCs and MC effects therapeutically. Specifically, we discuss the most common approaches for investigating the role and relevance of MCs in various diseases. We also review current therapeutic approaches aimed at modulating MC numbers, inhibiting MCs and/or preventing MC activation, modulating MC signal transduction and protection from the effects of MC mediators.
引用
收藏
页码：151 / 162
页数：12
相关论文
共 50 条
  • [1] Calpains as mechanistic drivers and therapeutic targets for ocular disease
    Vu, Jennifer T.
    Wang, Elena
    Wu, Jolan
    Sun, Young Joo
    Velez, Gabriel
    Bassuk, Alexander G.
    Lee, Soo Hyeon
    Mahajan, Vinit B.
    TRENDS IN MOLECULAR MEDICINE, 2022, 28 (08) : 644 - 661
  • [2] Role of mast cells in the pathogenesis of heart failure due to myocarditis: Mast cells as a therapeutic targets
    Higucih, H
    Miyamoto, T
    Kinoshita, M
    Yamada, T
    Uchiyama, K
    Matsumori, A
    JOURNAL OF CARDIAC FAILURE, 2004, 10 (04) : S43 - S43
  • [3] Should mast cells be considered therapeutic targets in multiple sclerosis?
    Pinke, Karen Henriette
    Goncalves Zorzella-Pezavento, Sofia Fernanda
    Lara, Vanessa Soares
    Sartori, Alexandrina
    NEURAL REGENERATION RESEARCH, 2020, 15 (11) : 1995 - 2007
  • [4] Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia
    Craig A Friesen
    Jennifer V Schurman
    Jennifer M Colombo
    Susan M Abdel-Rahman
    World Journal of Gastrointestinal Pharmacology and Therapeutics, 2013, (04) : 86 - 96
  • [5] Should mast cells be considered therapeutic targets in multiple sclerosis?
    Karen Henriette Pinke
    Sofia Fernanda Gon?alves Zorzella-Pezavento
    Vanessa Soares Lara
    Alexandrina Sartori
    NeuralRegenerationResearch, 2020, 15 (11) : 1995 - 2007
  • [6] Mast Cells and KIT as Potential Therapeutic Targets in Severe Asthma
    Galli, Stephen J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (20): : 1983 - 1984
  • [7] Mast cells: Therapeutic targets for COVID-19 and beyond
    Lam, Hiu Yan
    Tergaonkar, Vinay
    Kumar, Alan Prem
    Ahn, Kwang Seok
    IUBMB LIFE, 2021, 73 (11) : 1278 - 1292
  • [8] Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets
    von Buedingen, H. -Christian
    Palanichamy, Arumugam
    Lehmann-Horn, Klaus
    Michel, Brady A.
    Zamvil, Scott S.
    EUROPEAN NEUROLOGY, 2015, 73 (3-4) : 238 - 246
  • [9] Histones and their modifications in ovarian cancer-drivers of disease and therapeutic targets
    Marsh, Deborah J.
    Shah, Jaynish S.
    Cole, Alexander J.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [10] Mast Cells as Targets of Pimecrolimus
    Ma, Zhongcai
    Jiao, Zongjiu
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (34) : 3823 - 3829
12345